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ASSOCIATION OF VIRAL GENOME WITH GRAFT LOSS IN CHILDREN
AFTER CARDIAC TRANSPLANTATION
GIRISH S. SHIRALI, M.D., JIYUAN NI, M.D., RICHARD E. CHINNOCK, M.D., JOYCE K. JOHNSTON, R.N., B.S.,
GEOFFREY L. ROSENTHAL, M.D., PH.D., NEIL E. BOWLES, PH.D., AND JEFFREY A. TOWBIN, M.D.

ABSTRACT
Background The survival of recipients of cardiac
allografts is limited by rejection and coronary vasculopathy. The purpose of this study in children who
had received heart transplants was to evaluate the
cardiac allografts for myocardial viral infections and
to determine whether the presence of viral genome
in the myocardium correlates with rejection, coronary vasculopathy, or graft loss.
Methods We enrolled heart-transplant recipients
1 day to 18 years old who were undergoing evaluation for possible rejection and coronary vasculopathy.
Endomyocardial-biopsy specimens were evaluated for
evidence of rejection with the use of standard criteria
and were analyzed for the presence of virus by the
polymerase chain reaction (PCR).
Results PCR analyses were performed on 553 consecutive biopsy samples from 149 transplant recipients. Viral genome was amplified from 48 samples
(8.7 percent) from 34 patients (23 percent); adenovirus
was found in 30 samples, enterovirus in 9 samples,
parvovirus in 5 samples, cytomegalovirus in 2 samples, herpes simplex virus in 1 sample, and Epstein–
Barr virus in 1 sample. In 29 of the 34 patients with
positive results on PCR (85 percent), an adverse cardiac event occurred within three months after the
positive biopsy, and 9 of the 34 patients had graft loss
due to coronary vasculopathy, chronic graft failure, or
acute rejection. In 39 of the 115 patients with negative
results on PCR (34 percent), an adverse cardiac event
occurred within three months of the negative PCR
finding; graft loss did not occur in any of the patients
in this group. The odds of graft loss were 6.5 times
as great among those with positive results on PCR
(P=0.006). The detection of adenovirus was associated
with considerably reduced graft survival (P=0.002).
Conclusions Identification of viral genome, particularly adenovirus, in the myocardium of pediatric
transplant recipients is predictive of adverse clinical
events, including coronary vasculopathy and graft
loss. (N Engl J Med 2001;344:1498-503.)
Copyright © 2001 Massachusetts Medical Society.

C

ARDIAC transplantation in children is a
lifesaving procedure aimed at sustaining
long-term, productive survival. The major
short-term and long-term risks associated
with transplantation that limit survival include allograft rejection, coronary vasculopathy in the transplant, and lymphoproliferative disease, but the underlying causes of these disorders are not completely
understood. The diagnosis of allograft rejection relies
on histopathological criteria described by the International Society for Heart and Lung Transplantation
(ISHLT).1 We speculated that there might be an association between allograft rejection and viral infection in these patients.2 Classically, viral infections are
diagnosed by means of serologic tests and viral cultures, which are time-consuming and have limited
sensitivity and specificity.3 Today, molecular hybridization4-6 and polymerase-chain-reaction (PCR) analysis7-18 can be used to detect viral nucleic acid in body
fluid and tissue samples. Numerous studies of patients
with myocarditis have demonstrated the usefulness of
PCR analysis for etiologic diagnosis.7-17,19-22
It is known that there is an association between the
detection by PCR of viral genome in the myocardium
and concomitant rejection,2 but the long-term implications of this association are unclear. Our study
addressed the intermediate-term follow-up of pediatric cardiac-transplant recipients who underwent serial PCR analysis as part of the routine surveillance for
rejection, as well as patients with clinical evidence of
rejection and those who underwent repeated biopsy
after receiving treatment for rejection. The principal
hypotheses that we tested were that graft survival is
worse among patients who have positive PCR results
for viral genome than among those who have negative
results and that graft survival is worse among patients
who have more episodes of rejection. We also investigated the relation between the number of episodes
of rejection and the presence or absence of viral ge-
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nome on PCR, graft survival, or both, as well as
whether the type of virus detected by PCR influences the risk of graft loss and coronary vasculopathy in
the transplant.
METHODS
Between January 1993 and June 1998, serial PCR analysis was
performed prospectively on all right ventricular endomyocardialbiopsy samples obtained from children who were cardiac-transplant
recipients at Loma Linda University Children’s Hospital. These
children were enrolled in the study at the time of transplantation.
Biopsy samples were fresh-frozen in liquid nitrogen and stored at
¡80°C for up to one month before the analysis and then analyzed
in a batch. All samples were analyzed by PCR for adenovirus, cytomegalovirus, enterovirus, herpes simplex virus, parvovirus, and
Epstein–Barr virus. The PCR analysis was performed at a distant
site, the Baylor College of Medicine, in a prospective, blinded
fashion.
Viral cultures were obtained when they were clinically indicated,
but only a small percentage of samples were cultured. Histopathological grading of biopsy specimens was performed according to
ISHLT criteria.1 The standardized ISHLT criteria for the diagnosis of cardiac-allograft rejection ranged from grade 0 (no rejection)
to grade 4 (severe acute rejection with a diffuse, aggressive, polymorphous, inflammatory infiltrate and myocyte necrosis and damage associated with edema, hemorrhage, and vasculitis). Rejection
scores between 0 and 4 represent an increasing gradient of inflammation, with grade 3A representing multifocal inflammatory infiltrates (multifocal moderate rejection) with some myocyte damage
and grade 3B representing a diffuse inflammatory process with myocyte damage and edema.23 Echocardiograms were obtained and
graded for rejection prospectively by means of a previously described
system of multivariable computerized analysis. 24,25
Patients and Samples
We studied all children who had undergone heart transplantation for whom right ventricular endomyocardial-biopsy samples
were available. All patients were treated with a standard regimen
of cyclosporine and azathioprine. Rejection was treated with steroids, other antirejection medications, or both, on the basis of a clinical examination. Serial biopsy samples were obtained after the parents of the patient had given written informed consent and during
routine cardiac catheterization that was part of surveillance for rejection (according to the protocol), as well as from patients with
clinical evidence of rejection and as a follow-up procedure after a
patient was treated for rejection.
Control Samples
Cardiac-biopsy samples from age- and sex-matched patients with
no evidence of myocarditis, dilated cardiomyopathy, or other inflammatory processes were used as negative controls. These included
formalin-fixed samples obtained at autopsy and snap-frozen tissue
from explanted hearts that had been obtained at the time of transplantation from patients with congenital heart disease or hypertrophic cardiomyopathy.
Template Preparation and PCR
Samples were homogenized in RNAzol with the use of disposable manual homogenizers, and total RNA and DNA were isolated
as previously described.16,17,19 Reverse-transcriptase PCR was used
to detect enterovirus RNA, and PCR was used to detect the DNA
of adenovirus, cytomegalovirus, herpes simplex virus, parvovirus,
and Epstein–Barr virus.2,16,17,19-21
All samples were analyzed by technicians who had no knowledge
of the clinical or serologic data or the results of cultures, and all
assays were performed in duplicate. The presence of amplifiable nucleic acid in each sample was verified with the use of primers designed to amplify cellular nucleic acid (K-ras or b-actin).2,16,17,19-21

Statistical Analysis
Survival analysis was used to determine the differences in the incidence of graft loss associated with the findings on PCR analysis.
The Wilcoxon test was used to assess the statistical significance of
the difference in survival between patients with positive results on
PCR and those with negative results. Logistic regression was used
to determine the association between graft loss and the number of
episodes of rejection and to assess the independent associations
between the PCR results and graft loss as well as between the number of episodes of rejection and graft loss. Contingency-table analysis was used to determine whether, among those with positive results
on PCR, the presence of coronary vasculopathy in the transplant
was associated with graft loss. Fisher’s exact tests were used to determine the statistical significance of any associations found by the
contingency-table analyses. All P values were based on two-sided
statistical tests. An alpha level of 0.05 was used to reject the null
hypothesis of no difference between the groups. The Bonferroni
method was used to correct reported P values for the three statistical tests that addressed the two primary hypotheses. Nominal
P values are presented for the statistical tests that were used to address the secondary end points of the study, including virus type,
number of episodes of rejection, and association of graft loss with
virus type.

RESULTS
Samples and Patients

A total of 553 serial endomyocardial-biopsy samples from 149 patients were studied (range, 1 to 17 per
patient during the 5.5 years of study; median, 3 samples per patient). The median age of the patients at
the time of transplantation was 2.3 months (range,
0.1 to 216), and 657 patient-years of follow-up were
completed after transplantation (range, 4.2 to 145.3
months per patient; median, 47.6).
PCR Results

A viral product was amplified by PCR from 48 of
the 553 biopsy samples (8.7 percent) from 34 of the
149 patients (23 percent). In 30 samples (from 24
patients) adenovirus, usually type 2, was amplified
(Fig. 1). In addition, enterovirus was detected in nine
samples, parvovirus in five samples, cytomegalovirus
in two samples, and herpes simplex virus and Epstein–
Barr virus in one sample each. In seven patients, more
than one virus was detected during follow-up. Patients
first had positive results on PCR within 0.4 to 103.4
months after transplantation (median, 15.7). Followup continued for 64.8 patient-years after the first positive results were obtained; the median follow-up was
21.5 months (range, 3.1 to 55.6).
Adenovirus was detected during all seasons (Fig. 2),
whereas enterovirus appeared primarily in the winter
and autumn months. Other viruses (parvovirus, Epstein–Barr virus, or cytomegalovirus) were seen during the spring, summer, and autumn months. A contingency-table analysis was performed to assess the
homogeneity of the specific types of these viruses for
which patients tested positive and the seasons in which
they did so. No significant differences in seasonal variability were identified, although trends were seen (P=
0.09 by a global test for differences among seasons).
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Indications for Biopsy in PCR-Positive Cases

For all patients with positive results on PCR, charts
were retrospectively reviewed to determine the indications for endomyocardial biopsy. Of the 48 biopsy
samples with positive PCR results, 22 (46 percent)
were obtained because of clinically suspected rejection
(in 15 patients) or as a follow-up procedure after an
episode of rejection (in 7 patients). The other 26 biopsies with positive PCR results (54 percent) were obtained during routine surveillance for evidence of rejection.
The results of previous PCR testing were available
for the patients from whom 33 of the 48 PCR-positive samples were obtained (69 percent). Thirty of
these samples were from patients who had previously
had negative results on PCR, as compared with just
three from patients who had previously had positive
results. In six patients, virus was detected in the first
biopsy after transplantation; therefore, no previous
PCR results were available. No previous PCR testing
had been performed in the remaining nine patients
with positive results, all of which were obtained soon
after transplantation.
The results of subsequent PCR testing were available for the patients with 42 of the 48 PCR-positive
samples (88 percent). In 37 cases, the subsequent test
was negative, and in 5 cases, the subsequent test was
positive. One patient who tested positive for Epstein–
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Figure 1. PCR Analysis Showing Adenovirus DNA in a Right
Ventricular Endomyocardial-Biopsy Specimen of a Patient with
Acute Rejection.
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Figure 2. Seasonal Variation in the Amplification of Viral Genomes from the Biopsy Samples Obtained
from Pediatric Cardiac-Transplant Recipients.
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Barr virus underwent retransplantation because of coronary vasculopathy. A biopsy sample obtained after
retransplantation was also positive for Epstein–Barr
virus. Of the remaining six patients, two died shortly
after having a positive result on PCR, and a lack of
vascular access precluded repeated biopsy in the other four patients. Persistence of adenovirus was noted
(three patients had positive results on PCR on a total
of 10 occasions), as well as parvovirus (one patient had
positive results on PCR twice during a one-month
period).
Correlation between Positive PCR Results
and Clinical Conditions

There was no evidence of rejection (i.e., rejection
was assessed as grade 0 or 1), infection, or vasculitis
in the vast majority of biopsy specimens we evaluated according to the ISHLT criteria (518 of the 553
samples [94 percent] were negative). However, of the
35 samples with histopathological evidence of rejection (assessed as grade 3A or higher), 27 were associated with positive results on PCR (77 percent); the
remainder of the patients with such samples never had
positive PCR results, and in these cases, the rejection
occurred soon after transplantation (in six patients) or
was the result of noncompliance with immunosuppressive regimens (in two patients).
In 16 of the 34 patients with positive results on
PCR (47 percent), an endomyocardial-biopsy specimen was simultaneously graded 3A (indicating moderately high grade rejection). In six other instances,
a biopsy specimen classified as grade 0 (no rejection)
was found in association with chronic graft dysfunction (in three patients), new arrhythmias (supraventricular tachycardia in one patient and atrial flutter
in another) with heart failure, and death from coronary arteriopathy two days later (in one patient). In
contrast, a simultaneously obtained endomyocardialbiopsy specimen was graded 3A in only 8 of the 115
patients with negative results on PCR (7 percent) —
a significantly smaller proportion than among the
patients with positive results on PCR (odds ratio for
rejection associated with detection of virus, 11.9; 95
percent confidence interval, 4.4 to 31.8; P<0.001).
One or more adverse cardiac events occurred in 29
of the 34 patients with positive PCR results (85 percent) within three months before or after the positive
PCR analysis. These events included biopsy-verified
rejection in 26 patients, new or chronic ventricular
dysfunction in 7, and graft loss because of death in
1 and because of the need for retransplantation in 1.
In 11 patients, a simultaneously obtained biopsy specimen was assessed as grade 0, but biopsy-verified rejection occurred during the three months before the
positive PCR result was obtained (in 6 patients) or
thereafter (in 5 patients). Echocardiographic criteria
did not consistently predict rejection or adverse cardiac events. In contrast, an adverse cardiac event oc-

curred in 39 of 115 patients (34 percent) within three
months before or after a negative PCR result — a
significantly smaller proportion than among the patients with positive PCR results (odds ratio for an adverse cardiac event with a positive PCR result, 11.3;
95 percent confidence interval, 4.1 to 31.5; P<0.001).
These events consisted of concomitant biopsy-verified
rejection (in 8 patients) or rejection during the three
months before the negative result was obtained (in
26 patients) or thereafter (in 5 patients). Neither ventricular dysfunction nor graft loss occurred in any
patient with negative PCR results.
In order to address the possibility that the nature
of the patient pool might bias the results because it
included a disproportionate number of patients who
required biopsies for surveillance for rejection, a contingency-table analysis of PCR results (chi-square test)
was performed according to the indication for biopsy.
This analysis was restricted to the first PCR-tested biopsy specimen for each patient. Of the 149 patients
studied, rejection was suspected in 39 at the time of
their first biopsy; 8 of these patients were positive for
virus on PCR, whereas of the remaining 110 patients,
who underwent a biopsy as part of routine surveillance, only 6 had positive results for virus (odds ratio,
4.47; 95 percent confidence interval, 1.44 to 13.87;
P<0.01).
Outcomes

There was a statistically significant difference between the rate of graft survival among the patients
with positive results on PCR and the rate among those
with only negative results (Fig. 3). Graft loss occurred
in 9 of the 34 patients with positive PCR results (26
percent) 2 to 43.4 months after the first positive PCR
result was obtained (median, 28.9 months). In six of
these nine patients (67 percent), coronary vasculopathy developed in the transplant. One of these patients
died suddenly, and five were placed on the waiting list
for retransplantation; two of the five died while awaiting retransplantation, and three underwent retransplantation. Pathological examination of the three explanted hearts revealed severe (grade 3 or 4) coronary
vasculopathy. In one patient, parvovirus had been detected before the development of coronary vasculopathy; the patient subsequently died of aplastic anemia.
The other two patients are doing well after retransplantation.
Chronic graft failure developed in two of the three
patients with graft loss in whom coronary vasculopathy did not develop. One of these patients underwent
retransplantation and is doing well; the other patient
died. The third patient with graft loss but without coronary vasculopathy died of acute rejection. Thus, six
of the nine patients with graft loss died, as did one
patient with positive PCR results for Epstein–Barr
virus who had lymphoproliferative disease after transplantation.
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0.4

cent (P=0.002 for the comparison between adenovirus-positive patients and adenovirus-negative patients). The odds ratio for graft loss in adenoviruspositive patients, as compared with patients who had
persistently negative PCR results for adenovirus, was
4.7 (95 percent confidence interval, 1.3 to 17.1; P=
0.02). Because of the small numbers of patients with
positive results for other viruses, we could not make
a reliable determination of the relative risk of graft
loss for patients with those viruses.
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Figure 3. Kaplan–Meier Analysis of Actuarial Graft Survival in
Children with Positive PCR Results for Any Viral Genome at Any
Time on Serial Biopsies (PCR-Positive), as Compared with Those
Who Had Consistently Negative PCR Results (PCR-Negative).

Significance of the Detection of Virus

Viral genome was detected in 34 of 149 cardiactransplant recipients who underwent serial biopsies
(23 percent), and graft loss occurred in 26 percent.
The crude odds ratio for graft loss among patients
with positive results on PCR, as compared with those
with negative results, was 6.5 (95 percent confidence
interval, 2.1 to 19.9; Bonferroni-corrected P=0.006).
Among patients without positive results on PCR, the
five-year graft-survival rate was 96.1 percent, whereas
the rate among patients with positive results on PCR
was 64.7 percent (Bonferroni-corrected P=0.003)
(Fig. 3).
A greater number of episodes of rejection (associated with positive PCR results) was associated with a
higher risk of graft loss. Each episode of rejection
increased the risk of graft loss by 57 percent (95 percent confidence interval, 26 to 95 percent; Bonferroni-corrected P=0.009). In a multivariate logisticregression analysis, the association between positive
PCR results and graft loss was greatly diminished by
adjustment for the number of episodes of rejection,
suggesting that the association between positive PCR
results and graft loss was largely mediated by an increase in the number of episodes of rejection. The
mean number of episodes of rejection among patients
with positive PCR results was 2.1 times that among
patients with negative PCR results (P<0.001).
Association of the Type of Virus with Outcome

In patients with biopsy samples that were positive
for adenovirus, five-year graft survival was 62.3 per-

Our study demonstrates a close temporal association between the detection of viral genome and adverse cardiac events over the short term and identifies
the detection of viral genome as an independent predictor of graft loss over the intermediate-to-long term.
The association between cytomegalovirus infection
and allograft rejection, vasculopathy, and death is well
known.26-30 However, previous studies were retrospective, relying on serologic test results, and did not involve analysis of myocardial samples. Some studies
have shown an association between the presence of
adenovirus, enterovirus, or cytomegalovirus genome
in the myocardium and concomitant rejection.2
In this prospective, blinded study, adenovirus was
shown to be the most common agent associated with
adverse cardiac events, including graft loss, in both the
short and the long term. The next most common viral agents were enterovirus, cytomegalovirus, and parvovirus. Adenovirus and enterovirus are the most
common pathogens associated with myocarditis as
well,4-7,9,10,16,17 and adenovirus has been associated with
graft loss and bronchiolitis obliterans after lung transplantation.31 The association of a positive PCR assay
for virus with concomitant biopsy-verified rejection
is consistent with an episode resembling viral myocarditis: like myocarditis, a positive PCR result frequently occurred in the absence of evidence of inflammation.16,17,32-34 In this study, a concomitant biopsy
with no evidence of rejection (grade 0) was occasionally seen in association with an adverse cardiac event.
Previous or subsequent biopsy samples typically tested negative for virus on PCR but frequently revealed
signs of rejection. This combination of findings suggests a delayed immune response with a late expression of inflammatory mediators. Although our data
suggest that viral infection causes rejection, another
possibility is “reverse causality”: the transplanted heart
in the early phases of rejection could be more prone
to viral infection as a secondary phenomenon. However, this appears unlikely, since several of the patients we studied had a positive result on PCR even
when they had a biopsy assessed as grade 0, which is
not consistent with the presence of rejection. In these
patients, signs and symptoms of rejection later became apparent, within three months after the positive PCR result was obtained.
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The virus-mediated triggering or acceleration of
coronary arteriopathy after heart transplantation is not
yet understood. Cytomegalovirus has been implicated in the pathogenesis of atherosclerosis.35,36 Our study
implicates adenovirus and enterovirus in the development of post-transplantation coronary vasculopathy, but the mechanism is unclear. It is possible that
a persistent subclinical inflammatory response is responsible for this effect as well. Since pulsed steroid
therapy is commonly used as a first-line response to
rejection, it is plausible that the reduction in infiltrate is not representative of the immune response.
The understanding that viral infections result in late
rejection and other long-term sequelae should lead
to a reconsideration of the treatment options for late
rejection. The use of viral vaccines before transplantation could be considered for study, and the use of
intravenous immune globulin either prophylactically
or during the course of a rejection episode is another
possible option. Finally, the development of pharmaceutical antiviral agents to treat infected patients would
also be worthwhile.
Supported by funds from the National Institutes of Health, the Texas
Children’s Hospital Foundation, the Montgomery Heart Foundation, and
the John Patrick Albright Foundation (to Dr. Towbin); by a grant from the
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